Q1 2025 SCHOTT Pharma AG & Co KgaA Earnings Call Transcript
Key Points
- Schott Pharma AG & CO KGaA (WBO:1SXP) reported stable revenues of EUR 230 million, reflecting a 4% increase in constant currencies compared to the previous year's period.
- The company's EBITDA margin at constant currencies was 26.3%, indicating strong profitability.
- High Value Solutions (HVS) contributed to 55% of total revenues, showcasing successful execution of the growth strategy.
- The company has strong partnerships with over 1800 customers, including all TOP30 global pharma companies, with relationships averaging over 10 years.
- Significant market demand for HVS products is projected to result in a compound annual growth rate of 12%, outperforming the market.
- Reported revenues showed a slight decrease of 1% year over year.
- Earnings per share declined by 35% to EUR 0.19 due to EBITDA decline and higher depreciation.
- The EBITDA margin decreased from 31.3% in Q1 2024 to 25.1% in Q1 2025.
- The company experienced a negative impact from currency fluctuations, particularly from the US dollar and Argentine peso.
- Cash flow from operating activities decreased by EUR 42 million to EUR 24 million, impacted by lower EBITDA performance and a temporary increase in working capital.
&-
Hello, everyone. Thank you for joining SCHOTT Pharma's earnings call for the first quarter of the fiscal year 2025. I'm Tobias Erfurth, head of investor relations, and it's my pleasure to host today's call.
I'm joined by our CEO, Andreas Reisse and our CFO, Dr. Almuth Steinkühler. Andreas will kick off today's call by sharing key business and financial highlights. Following this, Almuth will take us through our financials for the 1st quarter in more detail.
Andreas, we conclude the presentation before we open the Q&A session. Please go ahead.
This came out, before we begin, I would like to draw your attention to our disclaimer, which we encourage you to be read. Additionally, please note that we talk about the fiscal year 2025. We're referring to the period from October 1st to September 30, 2025. This means that the first quarter relates to the period from October 1st to December 30, 2024. With this, I would now like to hand over to our CEO, Andreas Reisse.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
